Erica Weston1, Margarita Noel2, Kara Douglas2, Kelsey Terrones2, Francis Grumbine2, Rebecca Stone1, Kimberly Levinson3. 1. The Kelly Gynecologic Oncology Service, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 2. Greater Baltimore Medical Center, Towson, MD, USA. 3. The Kelly Gynecologic Oncology Service, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Greater Baltimore Medical Center, Towson, MD, USA. Electronic address: klevins1@jhmi.edu.
Abstract
OBJECTIVES: To evaluate the effects of an enhanced recovery after minimally invasive surgery (MIS-ERAS) protocol on opioid requirements and post-operative pain in patients undergoing minimally invasive hysterectomy on a gynecologic oncology service. METHODS: For this retrospective study, opioid use (oral morphine equivalents (OME)) and post-operative pain scores were compared between patients undergoing minimally invasive hysterectomy pre and post MIS-ERAS protocol implementation. Patients with chronic opioid use or chronic pain were excluded. Opioid use and pain scores were compared between groups using Wilcoxon Rank Sum, Student's t-test, and multiple linear regression. Compliance and factors associated with opioid use and pain scores were assessed. RESULTS: The MIS-ERAS cohort (n = 127) was compared to the historical cohort (n = 99) with no differences in patient demographic, clinical or surgical characteristics observed between groups. Median intra-operative and inpatient post-operative opioid use were lower among the MIS-ERAS cohort (12.0 vs 32.0 OME, p < .0001 and 20.0 vs 35.0 OME, p = .02, respectively). Pain scores among MIS-ERAS patients were also lower (mean 3.6 vs 4.1, p = .03). After controlling for age, BMI, operative time, length of stay, cancer diagnosis, and surgical approach, the MIS-ERAS cohort used 10.43 fewer OME intra-operatively (p < .001), 10.97 fewer OME post-operatively (p = .019) and reported pain scores 0.56 points lower than historical controls (p = .013). Compliance was ≥81% for multimodal analgesia elements and ≥75% overall. CONCLUSIONS: Enhanced recovery after minimally invasive surgery protocol implementation is an effective means to reduce opioid use, both in the intra-operative and post-operative phases of care, among gynecologic oncology patients undergoing minimally invasive hysterectomy.
OBJECTIVES: To evaluate the effects of an enhanced recovery after minimally invasive surgery (MIS-ERAS) protocol on opioid requirements and post-operative pain in patients undergoing minimally invasive hysterectomy on a gynecologic oncology service. METHODS: For this retrospective study, opioid use (oral morphine equivalents (OME)) and post-operative pain scores were compared between patients undergoing minimally invasive hysterectomy pre and post MIS-ERAS protocol implementation. Patients with chronic opioid use or chronic pain were excluded. Opioid use and pain scores were compared between groups using Wilcoxon Rank Sum, Student's t-test, and multiple linear regression. Compliance and factors associated with opioid use and pain scores were assessed. RESULTS: The MIS-ERAS cohort (n = 127) was compared to the historical cohort (n = 99) with no differences in patient demographic, clinical or surgical characteristics observed between groups. Median intra-operative and inpatient post-operative opioid use were lower among the MIS-ERAS cohort (12.0 vs 32.0 OME, p < .0001 and 20.0 vs 35.0 OME, p = .02, respectively). Pain scores among MIS-ERASpatients were also lower (mean 3.6 vs 4.1, p = .03). After controlling for age, BMI, operative time, length of stay, cancer diagnosis, and surgical approach, the MIS-ERAS cohort used 10.43 fewer OME intra-operatively (p < .001), 10.97 fewer OME post-operatively (p = .019) and reported pain scores 0.56 points lower than historical controls (p = .013). Compliance was ≥81% for multimodal analgesia elements and ≥75% overall. CONCLUSIONS: Enhanced recovery after minimally invasive surgery protocol implementation is an effective means to reduce opioid use, both in the intra-operative and post-operative phases of care, among gynecologic oncology patients undergoing minimally invasive hysterectomy.
Authors: Yuki Hirata; Russell G Witt; Laura R Prakash; Elsa M Arvide; Kristen A Robinson; Vijaya Gottumukkala; Ching-Wei D Tzeng; Paul Mansfield; Brian D Badgwell; Naruhiko Ikoma Journal: Ann Surg Oncol Date: 2022-05-04 Impact factor: 4.339
Authors: Abdelrahman AlAshqar; Ryota Ishiwata; Chailee Moss; Kathleen M Andersen; Lisa Yanek; Mark C Bicket; G Caleb Alexander; Mostafa A Borahay Journal: Am J Obstet Gynecol Date: 2022-03-03 Impact factor: 10.693
Authors: Richard H Parrish; Rachelle Findley; Kevin M Elias; Brian Kramer; Eric G Johnson; Leah Gramlich; Gregg S Nelson Journal: Ann Med Surg (Lond) Date: 2021-12-14
Authors: R Tyler Hillman; Maria D Iniesta; Qiuling Shi; Tina Suki; Tsun Chen; Katherine Cain; Loretta Williams; Xin Shelley Wang; Jolyn S Taylor; Gabriel Mena; Javier Lasala; Pedro T Ramirez; Larissa A Meyer Journal: Int J Gynecol Cancer Date: 2020-11-06 Impact factor: 3.437